Current status and perspective of CAR-T and CAR-NK cell therapy trials in Germany

por Albinger, Nawid, Hartmann, Jessica, Ullrich, Evelyn
Publicado 2021

Immunotherapy with NK cells: recent developments in gene modification open up new avenues

por Reindl, Lisa Marie, Albinger, Nawid, Bexte, Tobias, Müller, Stephan, Hartmann, Jessica, Ullrich, Evelyn
Publicado 2020

Arming Immune Cells for Battle: A Brief Journey through the Advancements of T and NK Cell Immunotherapy

por Wendel, Philipp, Reindl, Lisa Marie, Bexte, Tobias, Künnemeyer, Leander, Särchen, Vinzenz, Albinger, Nawid, Mackensen, Andreas, Rettinger, Eva, Bopp, Tobias, Ullrich, Evelyn
Publicado 2021

Primary CD33-targeting CAR-NK cells for the treatment of acute myeloid leukemia

por Albinger, Nawid, Pfeifer, Rita, Nitsche, Marcus, Mertlitz, Sarah, Campe, Julia, Stein, Katja, Kreyenberg, Hermann, Schubert, Ralf, Quadflieg, Melissa, Schneider, Dina, Kühn, Michael W. M., Penack, Olaf, Zhang, Congcong, Möker, Nina, Ullrich, Evelyn
Publicado 2022

P1354: CRISPR/CAS9 GENE EDITING OF IMMUNE CHECKPOINT RECEPTOR NKG2A IMPROVES THE ANTI-LEUKEMIC EFFICACY OF PRIMARY CD33-TARGETING CAR-NK CELLS.

por Albinger, Nawid, Bexte, Tobias, Al-Ajami, Ahmad, Wendel, Philipp, Buchinger, Leon, Gessner, Alec, Alzubi, Jamal, Särchen, Vinzenz, Vogler, Meike, Bhayadia, Raj, Klusmann, Jan-Henning, Möker, Nina, Cathomen, Toni, Rieger, Michael A., Imkeller, Katharina, Ullrich, Evelyn
Publicado 2023